vs
Side-by-side financial comparison of Canaan Inc. (CAN) and KalVista Pharmaceuticals, Inc. (KALV). Click either name above to swap in a different company.
Canaan Inc. is the larger business by last-quarter revenue ($20.8M vs $13.7M, roughly 1.5× KalVista Pharmaceuticals, Inc.). Canaan Inc. runs the higher net margin — -18.4% vs -361.4%, a 343.0% gap on every dollar of revenue.
Canaan Inc., doing business as Canaan Creative and known simply as Canaan, is a Singapore-based computer hardware manufacturer. Established in 2013 by N.G. Zhang, Canaan specializes in Blockchain servers and ASIC microprocessors for use in bitcoin mining.
KalVista Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the research, development and commercialization of novel oral serine protease inhibitor therapies. Its core pipeline addresses unmet medical needs for rare and inflammatory diseases including hereditary angioedema and diabetic macular edema, with primary target markets in North America and Europe.
CAN vs KALV — Head-to-Head
Income Statement — Q3 FY2025 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $20.8M | $13.7M |
| Net Profit | $-3.8M | $-49.5M |
| Gross Margin | 99.9% | 91.0% |
| Operating Margin | -15.9% | -336.3% |
| Net Margin | -18.4% | -361.4% |
| Revenue YoY | — | — |
| Net Profit YoY | — | -17.1% |
| EPS (diluted) | $-0.05 | $-0.92 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $20.8M | — | ||
| Q3 25 | $13.8M | $13.7M | ||
| Q2 25 | $11.4M | — | ||
| Q3 24 | $10.2M | $0 | ||
| Q2 24 | $4.8M | — |
| Q4 25 | $-3.8M | — | ||
| Q3 25 | $-1.5M | $-49.5M | ||
| Q2 25 | $-11.9M | — | ||
| Q3 24 | $-10.4M | $-40.4M | ||
| Q2 24 | $-5.4M | — |
| Q4 25 | 99.9% | — | ||
| Q3 25 | 99.9% | 91.0% | ||
| Q2 25 | 99.9% | — | ||
| Q3 24 | 99.9% | — | ||
| Q2 24 | 99.8% | — |
| Q4 25 | -15.9% | — | ||
| Q3 25 | -27.0% | -336.3% | ||
| Q2 25 | -45.5% | — | ||
| Q3 24 | -77.2% | — | ||
| Q2 24 | -193.9% | — |
| Q4 25 | -18.4% | — | ||
| Q3 25 | -11.0% | -361.4% | ||
| Q2 25 | -104.4% | — | ||
| Q3 24 | -102.7% | — | ||
| Q2 24 | -112.3% | — |
| Q4 25 | $-0.05 | — | ||
| Q3 25 | $-0.02 | $-0.92 | ||
| Q2 25 | $-0.25 | — | ||
| Q3 24 | — | $-0.87 | ||
| Q2 24 | — | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $243.5M |
| Total DebtLower is stronger | $6.2M | — |
| Stockholders' EquityBook value | $52.4M | $17.0M |
| Total Assets | $92.5M | $339.9M |
| Debt / EquityLower = less leverage | 0.12× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | — | ||
| Q3 25 | — | $243.5M | ||
| Q2 25 | — | — | ||
| Q3 24 | — | $31.8M | ||
| Q2 24 | — | — |
| Q4 25 | $6.2M | — | ||
| Q3 25 | $6.2M | — | ||
| Q2 25 | $6.2M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q4 25 | $52.4M | — | ||
| Q3 25 | $44.7M | $17.0M | ||
| Q2 25 | $33.8M | — | ||
| Q3 24 | $43.6M | $172.8M | ||
| Q2 24 | $56.8M | — |
| Q4 25 | $92.5M | — | ||
| Q3 25 | $81.7M | $339.9M | ||
| Q2 25 | $78.0M | — | ||
| Q3 24 | $69.3M | $200.2M | ||
| Q2 24 | $73.7M | — |
| Q4 25 | 0.12× | — | ||
| Q3 25 | 0.14× | — | ||
| Q2 25 | 0.18× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
